title: Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
authors.forename: E
authors.initials: E
authors.lastname: Mejstríková
authors.forename: T
authors.initials: T
authors.lastname: Kalina
authors.forename: J
authors.initials: J
authors.lastname: Trka
authors.forename: J
authors.initials: J
authors.lastname: Starý
authors.forename: O
authors.initials: O
authors.lastname: Hrusák
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology* / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology* / Q000378:metabolism; D002648:Child; D006801:Humans; D016130:Immunophenotyping; D015994:Incidence; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D011379:Prognosis; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3